SCHEMBL7262186

SCHEMBL7262186

[CH2]c1ccc(C)nc1C=Cc1ccccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.43
CYP1A1 P04798 1/20 0.43
CYP1B1 Q16678 1/20 0.43
KMT2A Q03164 4/20 0.42
MAPT P10636 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 3/20 0.42
KDM4E B2RXH2 2/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
FGFR1 P11362 1/20 0.41
FGFR3 P22607 1/20 0.41
RAB9A P51151 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CHAT P28329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714523 0.81 MEN1 (0.47) CYP1A2CYP1A1CYP1B1KMT2AMAPT
SCHEMBL4714522 0.81 MEN1 (0.47) CYP1A2CYP1A1CYP1B1KMT2AMAPT
SCHEMBL7262198 0.81 FGFR1 (0.44) CYP1A2CYP1A1CYP1B1KMT2AMAPT
SCHEMBL4711231 0.78 FGFR1 (0.41) CYP1A2CYP1A1CYP1B1KMT2AMAPT
SCHEMBL4711228 0.78 FGFR1 (0.41) CYP1A2CYP1A1CYP1B1KMT2AMAPT
SCHEMBL4713064 0.77 RAB9A (0.46) CYP1A2CYP1A1CYP1B1KMT2AMAPT
SCHEMBL4713060 0.77 RAB9A (0.46) CYP1A2CYP1A1CYP1B1KMT2AMAPT
SCHEMBL4710063 0.76 FGFR1 (0.40) CYP1A2CYP1A1CYP1B1KMT2AMAPT
SCHEMBL4710062 0.76 FGFR1 (0.40) CYP1A2CYP1A1CYP1B1KMT2AMAPT
SCHEMBL27497941 0.76 MAPT (0.51) CYP1A2CYP1A1CYP1B1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed